Solomon D Kattar

USPTO Granted Patents = 28 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 24 (Patent Applications = 22)

Average Co-Inventor Count = 12.3

ph-index = 9

Forward Citations = 224(Granted Patents)

Location History:

Medford, MA (US) (2009 - 2010)
Arlington, MA (US) (2011 - 2017)
Boston, MA (US) (2019)
Wakefield, MA (US) (2013 - 2021)

Company Filing History:

27 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

28 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

2. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

3. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

4. 9969749 - Inhibitors of IRAK4 activity (2018-05-15),

5. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),

6. 9932350 - Inhibitors of IRAK4 activity (2018-04-03),

7. 9926330 - Inhibitors of IRAK4 activity (2018-03-27),

8. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),

9. 9670196 - Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors (2017-06-06),

10. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

11. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),

12. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

13. 9353066 - Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors (2016-05-31),

14. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

15. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

Title: Solomon D Kattar: Pioneering Inventor Shaping the Future of Technology

Introduction:

Solomon D Kattar, an esteemed inventor based in Arlington, MA (US), is a visionary whose passion for innovation and relentless pursuit of excellence continue to inspire the next generation of inventors. With a remarkable portfolio of 27 patents, he is at the forefront of shaping the future of technology.

Latest Patents:

Solomon D Kattar's latest patents exemplify his dedication to pushing the boundaries of scientific discovery. His invention of Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors showcases his commitment to developing novel treatments for diseases such as Parkinson's Disease. Additionally, his tricyclic compounds as inhibitors of mutant IDH enzymes demonstrate his contribution to potential cancer treatments.

Career Highlights:

Having worked at renowned companies like Merck Sharp & Dohme Corporation and Merck Canada Inc., Solomon D Kattar has honed his skills and expertise in the field of pharmaceuticals and biotechnology. His inventive spirit and groundbreaking discoveries have earned him a reputation as a trailblazer in the industry.

Collaborations:

Throughout his career, Solomon D Kattar has collaborated with exceptional professionals such as Michael D Altman and Alan B Northrup. These collaborations have not only enriched his work but also fostered a culture of innovation and collaboration within the organizations he has been a part of.

Conclusion:

In conclusion, Solomon D Kattar's remarkable journey as an inventor has left an indelible mark on the world of technology and healthcare. His innovative solutions and unwavering commitment to excellence serve as a beacon of inspiration for aspiring inventors and researchers globally. Solomon D Kattar's legacy will undoubtedly continue to shape the landscape of innovation for years to come, paving the way for transformative advancements in science and technology.

This text is generated by artificial intelligence and may not be accurate.